SCYNEXIS (SCYX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Apr, 2026Executive summary
A special meeting is scheduled for May 19, 2026, to vote on a reverse stock split and reduction of authorized shares.
The reverse stock split ratio will be between 1-for-5 and 1-for-10, at the Board's discretion.
The proposal aims to help maintain compliance with Nasdaq's minimum bid price requirement and avoid delisting.
The Board recommends voting in favor of the proposal.
Voting matters and shareholder proposals
Only one proposal is up for vote: approval of an amendment to the Certificate of Incorporation for a reverse stock split and reduction in authorized shares.
Shareholders of record as of April 20, 2026, are eligible to vote.
Voting can be done online, by phone, mail, or during the virtual meeting.
The proposal requires a majority of votes cast to pass; abstentions and broker non-votes have no effect.
Shareholder proposals for the next annual meeting must be submitted by December 31, 2026.
Board of directors and corporate governance
The Board has full discretion to determine the reverse split ratio and whether to implement the split after shareholder approval.
The Board may abandon the reverse split even after approval if deemed not in the best interests of the company.
Latest events from SCYNEXIS
- Resale registration for 87M shares from a private placement; proceeds only from warrant exercises.SCYX
Registration filing1 May 2026 - Key votes include board elections, auditor ratification, and major share authorization changes.SCYX
Proxy filing1 May 2026 - Annual meeting seeks approval for director elections, equity plan expansion, and capital increase.SCYX
Proxy filing30 Apr 2026 - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.SCYX
Proxy filing27 Apr 2026 - Shareholders will vote on director elections, compensation, equity plan, and capital structure changes.SCYX
Proxy filing20 Apr 2026 - Acquisition of SCY-770 for ADPKD offers major commercial potential and no royalty obligations.SCYX
M&A announcement2 Apr 2026 - SCY-247 advances as a potent antifungal with strong clinical data and significant market potential.SCYX
investor presentation4 Mar 2026 - 2025 revenue rose sharply on GSK deals; SCY-247 clinical progress and cash runway extended.SCYX
Q4 20254 Mar 2026 - Advancing next-gen antifungal SCY-247 and expanding GSK partnership, with strong financials.SCYX
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026